MALLINCKRODT PLC
History
| Year | Detail |
|---|---|
| 1867 | The company was founded. |
| 1882 | Incorporates in Missouri as Mallinckrodt Chemical Works. |
| 1884 | Establishes its first office in New York City. |
| 1924 | Introduced iodeikon to the scientific community. |
| 1950 | Introduces UROKON SODIUM. |
| 1962 | The company acquired Van Pelt & Brown. |
| 1966 | Acquires Nuclear Consultants, Inc. of Maryland Heights, Missouri. |
| 1982 | Avon acquired Mallinckrodt. |
| 1986 | The company was acquired by the International Minerals and Chemical Corporation. |
| 1995 | Launched the company's first generic pharmaceutical. |
| 2000 | Mallinckrodt was acquired by Tyco International. |
| 2007 | Tyco Healthcare got separated from Tyco International and renamed itself as Covidien, an independent company. |
| 2012 | The company acquired CNS Therapeutics and its intrathecal therapy products. |
| 2015 | The company acquired Ikaria, Inc. |
| 2019 | The company completed the sales of wholly owned subsidiary BioVectra Inc. |
| 2021 | Received FDA approval of StrataGraft. |
| 2022 | Received FDA approval for Terlivaz. |
| 2024 | The company got U.S. FDA approval for supplemental new drug application for Acthar Gel. |
BCC Research Beacon 